Pell Bio-Med Technology Co., Ltd.
Pell Bio-Med Technology Co., Ltd., a biomedical company, engages in the development of cell culture technologies and techniques for therapeutic applications. Its commercial products include good tissue practice laboratory infrastructure, adipose-derived stem cells (ADSC) for regenerative medicine, and CIK and DC-CIK against cancers. The company also develops medicines for various types of cancers… Read more
Pell Bio-Med Technology Co., Ltd. (6949) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.061x
Based on the latest financial reports, Pell Bio-Med Technology Co., Ltd. (6949) has a cash flow conversion efficiency ratio of -0.061x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-75.72 Million) by net assets (NT$1.23 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Pell Bio-Med Technology Co., Ltd. - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how Pell Bio-Med Technology Co., Ltd.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Pell Bio-Med Technology Co., Ltd. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pell Bio-Med Technology Co., Ltd. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Top Resource Conservation Engineering Co Ltd
SHE:300332
|
0.021x |
|
Beijing Hualu Baina Film TV
SHE:300291
|
0.001x |
|
Midland States Bancorp Inc
NASDAQ:MSBIP
|
0.137x |
|
Gold Royalty Corp.
NYSE MKT:GROY
|
0.004x |
|
Jiangxi Ganneng Co Ltd
SHE:000899
|
0.125x |
|
MorningStar Partners, L.P.
NYSE:TXO
|
0.038x |
|
MedCap AB (publ)
ST:MCAP
|
0.104x |
|
Si-Bone Inc
NASDAQ:SIBN
|
0.014x |
Annual Cash Flow Conversion Efficiency for Pell Bio-Med Technology Co., Ltd. (2021–2024)
The table below shows the annual cash flow conversion efficiency of Pell Bio-Med Technology Co., Ltd. from 2021 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$1.29 Billion | NT$-260.12 Million | -0.202x | -32.74% |
| 2023-12-31 | NT$1.18 Billion | NT$-179.99 Million | -0.152x | +20.28% |
| 2022-12-31 | NT$814.60 Million | NT$-155.68 Million | -0.191x | +60.40% |
| 2021-12-31 | NT$224.87 Million | NT$-108.51 Million | -0.483x | -- |